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ABSTRACT
Unrelated-donor umbilical cord blood (CB) is a useful alternative hematopoietic stem cell source for patients
without suitably matched and readily available related or unrelated stem cell donors. Expectant parents today
may have the option of either donating the CB to a public CB bank or keeping and storing the CB in a private
bank for potential use in the future. The alternatives are often referred to as public banking and private banking.
On behalf of the American Society of Blood and Marrow Transplantation (ASBMT), we have reviewed the cur-
rently available data and opinions and offer the following recommendations:
1. Public donation of CB is encouraged where possible.
2. The probability of using one’s own CB is very small—difficult to quantify but probably as low as 0.04%
(1:2500) to 0.0005% (1:200,000) in the first 20 years of life—and therefore, storage of CB for personal use
is not recommended.
3. Family member banking (collecting and storing CB for a family member) is recommended when there is a sib-
ling with a disease that may be treated successfully with allogeneic transplant. Family member banking on be-
half of a parent with a disease that may be treated successfully with allogeneic transplant is only recommended
when there are shared HLA-antigens between the parents.
The committee acknowledges the expanding potential of indications for CB in the future, and suggests review of
these recommendations at regular intervals.
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In the 18 years since the first umbilical cord blood
(CB) transplant was reported in the New England
Journal of Medicine, the fields of CB research, banking,
and transplantation have flourished. CB transplanta-
tion has been used to successfully treat leukemia,
lymphoma, myelodysplasia, aplastic anemia (AA), he-
moglobinopathies, metabolic storage diseases, and
immunodeficiencies [1]. There are .250,000 CB
units stored in public CB banks for unrelated use,
and .8000 CB transplants have been performed [2].356Expectant parents today may have the option of either
donating the CB unit to a public CB bank or keeping
and storing the CB in a private bank for potential use
in the future. In this report, we review stem cell trans-
plantation using unrelated-donor CB, family member
(directed donor) CB, and autologous CB, using the
patient’s own stored CB. We touch briefly on poten-
tial additional uses of CB and how these may influ-
ence future recommendations. Finally, we state an
opinion on personal storage of CB. A summary in
lay terms for expectant parents is included at the
end of the report.
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TRANSPLANTATION
Human CB is one potential source of hematopoi-
etic stem cells (HSC) that is capable of reconstituting
hematopoiesis after myeloablative or nonmyeloabla-
tive therapy [2]. Multiple studies in patients with
hematologic malignancies have demonstrated that
cryopreserved CB from 4-6/6 HLA-A, -B antigen,
and -DRB1 allele matched unrelated donors contain
sufficient numbers of HSC to achieve engraftment in
most pediatric patients [1,2]. More recent data demon-
strate promising results in larger children and adults,
as well as patients with nonmalignant disorders [1-4].
Clinical experience has highlighted two chief benefits
of unrelated donor CB. First, as a cryopreserved
HSC source, CB is rapidly available with an absence
of donor attrition, and has the advantage that a trans-
plant can be scheduled according to patient needs
rather than donor availability. Second, in comparison
to adult HSC graft, the incidence of graft-versus-
host disease (GVHD) is lower in unrelated CB trans-
plants without the loss of a graft-versus-malignancy
effect [5].
However, the low cell content of CB units may be
its major limitation. Multiple studies have demon-
strated the adverse effect of low cell dose upon engraft-
ment, treatment-related mortality (TRM), and
survival [1,2,6]. The limitation of cell dose contributed
to the inferior hematopoietic recovery, increased
TRM, and inferior survival of adult single unit CB
transplant recipients (n 5 169) compared to that of 6
of 6 matched unrelated volunteer bone marrow (BM)
recipients (n5 367) reported by Laughlin et al [6].No-
tably, disease-free survival (DFS) after CB transplant
was comparable to that of HLA-mismatched BM
recipients (n 5 83), highlighting CB transplantation
as a viable alternative to HLA-mismatched volunteer
donors for adult recipients. In addition, a similar eval-
uation by Eurocord revealed comparable outcomes
after unrelated donor BM and CB transplant in adults
[7]. Finally, the use of double unit grafts as a strategy to
augment graft cell dose has been associated with
improved engraftment and reduced TRM compared
to single-unit historic controls with a DFS at 1 year
of 70% in patients transplanted in remission [3]. Fur-
thermore, comparable results following CB transplant
with reduced intensity (RIC) or nonmyeloablative con-
ditioning regimens highlights the suitability of CB for
patients unsuitable for ablative conditioning [4,8].
No randomized trials have compared transplanta-
tion using grafts from unrelated volunteer donors ver-
sus CB. However, a retrospective evaluation has
recently compared the outcomes of 4-6 of 6 HLA-A,
-B antigen, and -DRB1 allele-matched single-unit
CB transplantation with those of 8 of 8 allele-matched
unrelated volunteer donor transplants in children\16years with leukemia [5]. In comparison to an 8 of 8
matched adult donor, the 5-year DFS after 6 of 6
matched CB transplant (n 5 35) was superior. These
results support the use of HLA-matched CB in prefer-
ence to matched BM, or of mismatched CB if a unit of
adequate cell dose is available for the treatment of chil-
dren with leukemia.
In children, CB has been used to successfully treat
young children with metabolic diseases, such as adre-
noleukodystrophy and infantile Krabbe’s disease
[9,10]. Wider use of CB in adults is dependent on im-
provement in TRM compared with marrow or periph-
eral blood stem cell (PBSC) transplants. Thus, if
engraftment can be improved, as has been seen with
more recent experience using fludarabine (Flu)-based
conditioning and/or double unit grafts, the argument
in favor of CB in both adults and children will be
even further strengthened because of the lesser inci-
dence of chronic GVHD (cGVHD) and the likely con-
sequent improvement in quality of life.
CB COLLECTION, PROCESSING, AND
CRYOPRESERVATION
To provide suitable CB units for transplantation,
banks have been developed to collect, process, and
cryopreserve CB. There are 3 major kinds of CB col-
lection and storage: (1) CB units that are donated for
public use; (2) CB units that are collected from
a healthy newborn and stored for another family mem-
ber who suffers from a disease that is known to be
treatable by HSC transplantation (‘‘directed donor’’
CB collection), and (3) CB units that are collected
from a healthy newborn and stored for a fee for private
use in anticipation that the CBmay someday be needed
as therapy for autologous or family-member use.
There are two generally accepted methods for col-
lecting CB following delivery of the newborn baby.
One is to collect the blood immediately after delivery
prior to placental separation from the wall of the
uterus. The other way is to deliver the placenta with
the cord clamped and pass it from the operative or de-
livery field to an attendant who performs the CB col-
lection. Several studies have compared CB units
collected by both techniques, and, in aggregate, they
do not demonstrate consistent or significant differ-
ences in total blood volume, CD341 count, or total
nucleated cell count between the methods [11]. The
major issues in obtaining high-quality units for trans-
plantation are maximizing the volume of blood col-
lected, avoiding microbial contamination, and
avoiding undue delays that could result in clotting of
the specimen.
Optimal CB unit processing, cryopreservation,
and storage are critical to ensuring the safety and
potency of the graft. The most common technique in-
volves sedimentation of CB red blood cells followed by
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volume that is mixed with a cryopreservative solution
(typically DMSO), followed by controlled rate freez-
ing and storage in liquid nitrogen. An alternative pro-
cessing technique that is designed to minimize both
handling during processing and nucleated cell loss in-
volves volume reduction by a single centrifugation step
and results in a CB product that contains nearly all of
the original leukocytes and red blood cells prior to
freezing. Early studies reported that stepwise postthaw
CB dilution to decrease osmolality, followed by wash-
ing, was important to maintain CB progenitor cell
viability and engraftment speed, but recent clinical
studies show that postthaw CB dilution without wash-
ing, or even direct infusion of thawed CB, is associated
with equally reliable engraftment and freedom from
side effects [12].
CB for Family Use
Although there is less published literature on
family-member CB transplantation, HLA-matched
related-donor CB transplantation has been demon-
strated to be an effective therapy for patients with
hematopoietic disorders [13]. Eligibility determina-
tion of newborn donors and their mothers for family
member medically indicated CB donation usually em-
ploy strict quality control criteria. However, less strin-
gent eligibility criteria than is used for public CB
donation may be appropriate in some instances. For
example, a maternal history of hepatitis would disqual-
ify donation to a public CB bank, but in related CB
banking this exclusion would commonly be waived if
the mother had negative testing for actively infectious
hepatitis.
Most public unrelated-donor CB banks are orga-
nized to also support medically indicated CB collec-
tion and banking from related donors. In addition,
the National Institutes of Health (NIH) has funded
one CB bank with specific expertise in family banking,
especially for children with hemoglobinpathies. This
bank, the Children’s Hospital Oakland Sibling Donor
Cord Blood Program, is the largest publicly funded
CB bank for the purpose of medically indicated family
banking, and collects CB almost anywhere in the
United States if the medical indication is appropriate.
It currently stores .3000 CB units for specific poten-
tial transplant recipients who have accepted indica-
tions for transplant (49% for malignant conditions,
28% sickle cell disease, 6% thalassemia, 17% other
nonmalignant). As of 2006, this CB bank had facili-
tated 65 identical sibling or related-donor transplants,
51 using CB as the sole source of the graft, 23 patients
with MDS/acute leukemia, 21 with thalassemia, 12
with sickle cell disease, and 9 with other nonmalignant
conditions [14,15]. Graft failure occurred in 3% of pa-
tients, and TRM was 6%. Overall survival (OS) andDFS rates at 16 months were 80% and 76%, respec-
tively, and 93% and 88%, respectively, for those pa-
tients with nonmalignant conditions. These results
confirm the feasibility and support the efficacy of sib-
ling donor CB transplants for certain hematologic dis-
orders, metabolic disorders, and other diseases.
However, there is little experience with using a 3 of 6
matched CB unit stored for a parent.
In consideration of the above information and
studies, family member (directed donor) CB banking
can be recommended in the following situations:
1. A sibling of the expected child has a disease that can
be successfully treated with hematopoietic stem cell
transplantation (HSCT). Such diseases include leu-
kemia, lymphoma, a hemoglobinopathy, and bone
marrow (BM) failure syndrome.
2. The parent of the expected child has a disease
that can be successfully treated with HSCT,
and there are shared HLA antigens between the
parents.
CB for Personal Use
The business of personal storage of CB has grown
considerably, particularly in the United States. There
are numerous private CB banks that charge a fee to col-
lect and store CB for private use. The reasons for wide-
spread private banking include: (1) parental interest in
giving their children ‘‘biologic insurance’’ in case a dis-
ease develops in future years that can be treated with an
autologous stem cell transplant, and (2) aggressive
marketing by banks offering private collection and
storage of CB. In addition, the economics of CB bank-
ing, which are extremely labor- and resource-inten-
sive, have enabled a rapid expansion of private
banking. A public bank recovers costs only when CB
units are shipped for transplant, whereas a private
bank receives immediate income when the CB unit is
collected and ongoing annual income for maintenance
of the stored unit.
Our committee conducted a telephone survey of
private CB banks in the United States. Susan Stewart
from our committee contacted medical or other repre-
sentatives of 17 private CB banks, representing a com-
bined inventory of approximately 460,000 units [16].
Eleven responded, including three with written re-
sponses. Survey questions included information on
the number of CB units stored and the number of units
provided for transplantation, the diseases transplanted,
and whether the CB units were used for autologous or
family-member transplant. Information on costs of
collection and storage was not obtained. The respond-
ing banks reported a total of 99 units that have been
shipped for transplantation. Two of the largest banks
(Cord Blood Registry and Viacord) noted that the
bulk of their collections have been in the past 5 years,
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known at this time. In addition, they suggested that
medical uses for autologous CB units may expand in
the future, making the units more useful.
There are little data available concerning the out-
come of transplantation using privately banked CB
units. However, there are a few case reports of person-
ally stored CB units collected at birth that have been
used for autologous transplantation in later life. The
first such case, published in 1999, described a 14-
month-old child with neuroblastoma, who had CB
collected at birth because her brother had acute mye-
logeneous leukemia (AML) [17]. She received an au-
tologous CB transplant and was alive and disease
free 14 months after transplantation. Fruchtman and
colleagues [18] reported on a successful autologous
CB transplant for severe AA, following liver failure
and liver transplantation. Two patients with severe id-
iopathic AA, developing at the ages of 5 and 9, respec-
tively, were reported at the 2007 BMT Tandem
Meetings [19]. Both patients are alive and well, with
normal blood counts with a posttransplant follow-up
of 8 and 3 months, respectively. Hayani and colleagues
[20] have recently reported the first case of an autolo-
gous CB unit being used for the treatment of leuke-
mia. A 3-year-old girl with acute lymphoblastic
leukemia (ALL) with an isolated central nervous sys-
tem (CNS) relapse received an autologous CB trans-
plant using cryopreserved CB cells stored privately
at her delivery. The patient is disease free 24 months
after transplant.
The use of autologous CB for autoimmune disease
is under preliminary investigation. Haller and col-
leagues [21] treated 7 children with type I diabetes
with autologous CB infusion; these children had lower
insulin requirements and hemoglobin A1c than a ran-
domly selected population of severe diabetic children.
The Cord Blood Registry reports that 11 autologous
CB units have been used for transplant for indications
including aplastic anemia, cerebral palsy, traumatic
brain injury, and immune deficiency, but no outcome
data have been published on these transplants.
Concerns about storage of CB for future autolo-
gous use include:
 Probability of clinical need. It is difficult to estimate the
likelihood of use of an autologous CB unit collected
at the birth of a healthy baby. Using the probability
of developing cancer, the need for transplantation,
and the lack of a matched allogeneic donor, esti-
mates of the likely use of a stored autologous CB
unit are imprecise but would appear to range from
1:2500 (0.04%) to 1:200,000 (0.0005%) [22-26].
Autologous transplant can be efficacious for patients
with diseases such as lymphoma, myeloma, and neu-
roblastoma, and in many cases autologous marrow
or peripheral blood is adequate, or an allogeneicHSC is preferred. However, patients with genetic
marrow failure and immunodeficiency syndromes,
metabolic storage diseases, and hemoglobinopathies
who need a transplant require an allogeneic trans-
plant and a donor [22]. Therefore, privately stored
CB would be of no use for treating these diseases.
 Latent disease. The abnormal or diseased cells that
cause disease later in life may be present in the pa-
tient’s preserved CB, and may not be detectable.
For example, investigators have found that leukemic
blood cells are present in the neonatal blood of chil-
dren later diagnosed with leukemia. In the report of
Rowley et al [27], 3 children, aged 2, 5, and 6 with
acute lymphoblastic leukemia and the chromosome
translocation t(4;11), had their Guthrie cards (filters
containing newborn blood) examined and were
found to have the t(4;11) abnormal cells at birth.
For these reasons, public banks discard CB units
from their inventories if the donor is subsequently
diagnosed with leukemia. There have been no pub-
lished reports of CB grafts containing detectable
leukemia cells, but the malignant cells may be below
the level of routine detection.
 Quality and viability. The standards for public CB
banking and for private CB banking may differ in
terms of maternal eligibility and nucleated cell count
requirements, and these factors may influence the
overall quality of the stored CB. Long-term viability
of personally banked CB cells is also a concern, as
the CB cells collected at birth may not be used for
many years. CB has been found to be viable 15 years
after cryopreservation, but there are no data beyond
this time point [28,29].
 Graft-versus-leukemia (GVL) effect. The high relapse
rates after autologous or syngeneic transplants and
the benefit of a GVL effect of an allogeneic trans-
plant suggests that autologous CB would not be
the optimal cell source for patients with leukemia
needing a transplant.
In consideration of the above information and
studies, the following recommendations are offered:
1. The expectant parents should be encouraged to
donate their newborn’s CB to a public bank when
possible.
2. Expectant parents should be informed that, al-
though private CB banking is available for pur-
chase, the chance of personally stored CB being
of benefit to their child is extremely low (about
the same chance of maternal death during child-
birth), and that current knowledge is limited as to
the long-term CB viability and the likelihood of
success of autologous CB transplantation.
3. Parents who nevertheless choose to store CB for
personal use should be advised to carefully review
their contract and financial responsibilities, and to
360 K. K. Ballen et al.inquire about quality standards, median nucleated
cell dose of stored units, and accreditation of the
CB bank.
FUTURE NEED AND USES OF CB
Unrelated-donor CB as a public resource is likely
to be of increasing importance in the future. CB may
become the preferred HSC source for some patients,
even those with allele level matched unrelated volun-
teer donors. Also, because the required HLA match
is less stringent with CB than with unrelated volunteer
donors, access to transplantation can be expanded to
more racial and ethnic minorities that have a smaller
pool of registered potential donors.
Already data suggest that 6 of 6 A, -B antigen, and
-DRB1 allele-matched CB is superior to 8 of 8 allele
matched-unrelated BM transplantation in children
with leukemia, with 5 of 6 CB transplantation being
comparable but with less GVHD [5]. If the CB inven-
tory can be expanded such that the majority of patients
would have at least 5 of 6 matched CB grafts of ade-
quate size, CBmay well outperform fully matched vol-
unteer donors, or at least be comparable with less
GVHD. This is of particular significance, given the in-
creased use of peripheral blood unrelated volunteer
grafts and the associated significant incidence of
cGVHD. Expansion of the use of CB grafts in adult
transplantation will be facilitated by development of
reliable methods to diminish graft failure rates, en-
hance engraftment speed, and immune recovery, all
without increasing GVHD. Further, the National
Marrow Donor Program has documented that the
genetic heterogeneity of the U.S. population is in-
creasing (NMDP, 2007, personal communication).
Therefore, the numbers of patients without suitably
matched volunteer donors will likely increase, and
will be further compounded as access to health care
is improved for racial minorities. Finally, CB could
be an HSC resource that is readily available in the
event of a mass radiation accident or bioterrorism at-
tack, rendering a large number of people to need trans-
plant at short notice. For all of these reasons the
ASBMT and the transplant community have strongly
encouraged support of public CB banking and re-
search initiatives toward the further development of
this important resource for hematopoietic grafts.
Other potential uses for CB outside the field of
oncology might include transplantation of nonhema-
topoietic stem cells that are present in CB (eg, mesen-
chymal stem cells and other as-yet unrecognized stem
cell populations), or might take advantage of increased
plasticity of CB stem cells and their ability to differen-
tiate into alternative tissues such as endothelium, bone,
cartilage, neural, or cardiac cells, or their ability to
express transfected genes. Preclinical investigations
have employed CB mononuclear cells in the therapyof neurologic disease (stroke, spinal cord, or brain
trauma, amyotropic lateral sclerosis), cardiac disease
(myocardial infarction or ischemia, cardiac injury,
valve repair), and tissue repair [30-33]. Whether CB
will eventually be useful in treating these diseases is un-
clear; the usefulness of privately banked CB for the
treatment of nonhematopoietic and other diseases is
unknown. It is possible, but not yet known, whether
privately banked CB eventually might be used for
treatment of nonmalignant conditions and have wider
applications.
In summary, the uses of CB stored in public banks
are likely to increase in future years; expanded use of
CB stored for personal or family use is also possible.
For the foreseeable future, however, the likely use of
privately stored CB is exceeding small. Therefore, we
recommend priority to public donation of CB when-
ever possible. However, emerging data should be
reviewed, and these recommendations should be
assessed periodically.
RECOMMENDATIONS OF OTHER ORGANIZATIONS
Our committee has reviewed the findings and con-
clusions of other organizations that have studied these
issues, including those in the fields of pediatrics and
obstetrics and international medical organizations
and government agencies. There is overwhelmingly
consistency in their conclusions about current and
future uses of CB.
Pediatrics and Obstetrics
Prospective parents aware of the availability of
pubic and private CB storage frequently ask their ob-
stetrician or pediatrician for advice about the alterna-
tives. To assist their members to respond to these
queries, both the American College of Obstetricians
and Gynecologists (ACOG) and the American Acad-
emy of Pediatrics (AAP) have prepared formal position
statements [34,35]. Both medical associations strongly
encourage parents to donate their children’s CB to
public banks if those opportunities are available in
their geographic area. They also encourage parents
to consider directed donor storage if there is a first de-
gree relative with a disease or disorder that is known to
be treatable by CB transplantation. Both organizations
discourage parents from purchasing private storage
for CB as ‘‘biologic insurance’’ against the possibility
that their child might some day need the CB back for
transplantation.
Both organizations express serious concerns about
the tactics that some banks use to market private stor-
age to expectant parents who have relatively short time
to investigate the issues and make an informed deci-
sion. These tactics often include exaggerated claims
about the lifetime vulnerability of the newborn child,
the benefit of having stored CB, and their obligations
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endorse informed consent prior to arrival in the labor
and delivery suite, testing of units for infectious dis-
eases, and disclosure of test information to parents.
Finally, the AAP recommends that, if a physician or
nurse is compensated in any way to counsel or recruit
parents to privately bank their newborn’s CB, that fact
should be disclosed to the parent.
International
Several organizations in Europe have published
position statements on CB storage for personal use.
Worldwide, there are approximately 134 private banks
with an estimated 780,000 CB units stored [36]. The
European Union’s position states, ‘‘The possibility of
using one’s own cord blood stem cells for regenerative
medicine is currently purely hypothetic. Research in
this field is only at a very early stage. the legitimacy
of commercial cord blood banks for autologous use
should be questioned as they sell a service that has pres-
ently no real use regarding therapeutic options’’ [37].
In Italy and France, the sale of CB collection and
storage services for personal use is illegal. In Spain it
is permitted by law.
CONCLUSIONS
Since the first report of a successful CB transplant
almost 20 years ago, the uses of CB have expanded rap-
idly and CB banking has flourished.
The chance of a CB unit being released for trans-
plant from a public bank is at least 100 times greater
than that of a privately banked unit. Yet, the number
of CB units privately stored for personal or family
use is currently 3 times greater than the number of
units in public banks. CB is a valuable community re-
source, and expectant parents should be educated to
make informed decisions about its uses. To assist ex-
pectant parents in making an informed decision, the
committee has prepared a summary of its findings,
conclusions, and recommendations in lay terms using
a question-and-answer format (see Appendix).
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ASBMT Committee Report 363APPENDIX: SHOULD YOU STORE YOUR BABY’S
UMBILICAL CORD BLOOD? SOME FACTS TO HELP GUIDE
YOUR DECISION
Why Collect Umbilical Cord Blood?
In recent years, doctors have successfully treated
patients with life-threatening diseases, such as leuke-
mia, by transplanting them with blood collected from
the umbilical cord of a healthy baby. This new treat-
ment, called cord blood transplantation, has prompted
many expectant parents to consider storing their new-
born’s umbilical cord blood for possible future use.
Can I Collect and Store Cord Blood for My Own
Baby in Case It’s Needed?
Yes, but the chance of using one’s own cord blood
is very low—currently less than 4/100th of 1%. Many
patients who need a cord blood transplant need cells
from a donor, not their own blood cells, to cure their
disease. Their own cord bloodmay carry the same cells
that caused their disease. Frequently, brothers and sis-
ters are the best match as donors. Otherwise, public
registries such as the National Marrow Donor Pro-
gram can find unrelated cord blood or adult volunteer
donors for many people who need a transplant.
Can My Baby’s Cord Blood Help a Family Member
or Friend?
If the baby has a brother or sister with a disease that
can be treated by a cord blood transplant, banking the
baby’s cord blood can make sense, and may be recom-
mended by your doctor. For such families, the Chil-
dren’s Hospital Oakland Sibling Donor Cord Blood
Program (CHORI) specializes in banking cord blood
at no charge. Several public cord blood banks also
bank cord blood for families who have an identified
need for the cells.
Collecting and keeping a baby’s cord blood may be
recommended if the baby’s parent has a disease that
can be treated by transplant, both parents share genetic
markers called HLA antigens, and if a better donor is
not available. Banking cord blood for family members
other than the baby’s siblings or biologic parents is not
advised without the doctor’s guidance, because it is un-
likely that the cord blood unit will be useful.
Can I Donate My Baby’s Cord Blood to Someone
Who Needs It?
Donating your baby’s cord blood to a public bank
is encouraged whenever possible. A list of banks that
accept donations of cord blood can be found on the
National Marrow Donor Program Web site at
www.marrow.org under Donor Information or phone
800-627-7692. Not all hospitals collect cord blood,
and not all cord blood units can be accepted for storage
because of the health history of the parents, the volume
of the cord blood collected, or other considerations.Is the Procedure Used to Collect Cord Blood Safe
for My Baby?
Yes. The cord blood is collected after the baby has
been delivered and poses no risk to the newborn child
or mother. However, there may be some situations
when it is not advisable to collect cord blood, such as
if you are having twins or yourbaby is premature. Please
check with your doctor before making a decision.
WhatDoes It Cost to Donate or StoreCord Blood?
There is no cost to parents for donating cord
blood. Private storage for personal use usually requires
an initial fee plus an annual maintenance fee.
Where Can I Get More Information?
You can get more information from the following
resources:
 National Marrow Donor Program at 1-800-627-
7692 or www.marrow.org
 Blood and Marrow Transplant Information Net-
work at 1-888-597-7654 or www.bmtinfonet.org
 A Parents Guide to Cord Blood Banks http://paren-
tsguidecordblood.org
What can I do with My Baby’s Umbilical Cord
Blood?
Donate it to someone who needs a transplant.
U Recommended by American Society of Blood &
Marrow Transplantation, the American College
of Obstetricians and Gynecologists, and the Amer-
ican Academy of Pediatrics.
U Call National Marrow Donor Program at 800-627-
7692orvisitwww.marrow.org/DONOR/index.html
for a list of cord blood banks accepting donations
Store it for private use because the baby’s parent or
sibling has a disease that can be treated by a cord blood
transplant.
U Recommended by American Society of Blood &
Marrow Transplantation, the American College
of Obstetricians and Gynecologists, and the Amer-
ican Academy of Pediatrics.
U Call Children’s Hospital Oakland Sibling Donor
Cord Blood Program (CHORI) at 510-450-7600
or the National Marrow Donor Program (see
above) for more information
Store it for private use in the future, in case a need
arises.
U NOT recommended by American Society of Blood
&Marrow Transplantation, the American College
of Obstetricians and Gynecologists, and the Amer-
ican Academy of Pediatrics.
U Contact a private cord blood bank. A list of private
banks can be found online at http://parentsguide-
cordblood.org
